Biotechnology News

2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory...

New findings highlight the therapy’s ability to preferentially destroy MGMT-positive tumor cells, the specific population that survives standard treatments and drives disease recurrence. TAIPEI,...

SAN FRANCISCO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Claris Biotherapeutics, Inc., a late-stage biopharmaceutical company dedicated to advancing transformative therapies for sight-threatening...

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Precision Neuroscience Corporation (Precision), a brain–computer interface (BCI) technology company, today announced that it has closed an oversubscribed...

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, a biotech company harnessing the power of the innate and adaptive immune system, today announced the enrollment of the second...

In a preclinical chronic colitis model, Tvardi’s oral small molecule accumulated in the colon at approximately 8-fold higher concentrations than in plasma, at pharmacologically relevant levels, and...

Oral Presentations Highlight Phase 2 Vision Protection and Enrollment of a Consistent Phase 3 Patient Population Well-Positioned to Replicate Phase 2 Vision Outcomes ARCHER II is the First Pivotal...

SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Biolinq Incorporated, a pioneering developer of precision multi-analyte biosensors to improve metabolic health, today announced that the U.S. Food and...

NMPA approval supported by a 200-subject, randomized, controlled study in China demonstrating statistically significant improvement in mid-to-lower facial wrinkles and a favorable safety profile ...

Immuneering to Present at the ESMO Congress 2026